Cancer risk with methotrexate-TNF antagonist combination therapy compared to TNF-antagonist monotherapy in IBD

Inflammatory Bowel Disease

Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResource

Inflamm Bowel Dis

Yan K, Vuyyuru SK, Taylor A, Figueredo G, Raine T, Sanon M, Naessens D, Munje C, Moran GW

doi: 10.1093/ibd/izaf276

Inflammatory Bowel Disease

Comparative Risk of Serious Infections Associated With Treatment of Inflammatory Bowel Disease

Inflamm Bowel Dis

Khan N, Sundararajan R, Patel D, Patel M, Bahirwani J, Mahmud N

doi: 10.1093/ibd/izaf218

Colonoscopy

Individuals with polyps ≥10mm without other high-risk features have a similarly low post-colonoscopy colorectal cancer risk as those with no polyps

Endoscopy

van Roermund NS, van Leerdam ME, Spaander MCW, Dekker E, IJspeert JEG

doi: 10.1055/a-2730-6060

Inflammatory Bowel Disease

Safety and outcomes of advanced IBD therapies in patients with HIV: a propensity-matched cohort analysis

Inflamm Bowel Dis

Kaur A, Kaur A, Goren I

doi: 10.1093/ibd/izag015

ColonoscopyGastrointestinal Cancer

Utility of quantitative fecal immunochemical test values for average risk colorectal cancer screening risk stratification among patients with a positive test

Am J Gastroenterol

H-E Kang J, Jensen CD, Merchant S, Selby K, Badalov JM, Corley DA, Levin TR, Lee JK

doi: 10.14309/ajg.0000000000003805

Gastrointestinal Cancer

Dietary Iron Intake and Risk of Gastric Cancer

Cancer Epidemiol Biomarkers Prev

Pham YT, Nguyen BN, Nguyen TG, Hoang AH, Nguyen TT, Nguyen TT, Nguyen PMT, Pham TH, Cullen J, Nguyen H, Nguyen TC, Luu HN, Le TN

doi: 10.1158/1055-9965.EPI-25-1167

Inflammatory Bowel Disease

Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis

Inflamm Bowel Dis

Nishida Y, Hosomi S, Fujimoto K, Kobayashi Y, Nakata R, Maruyama H, Ominami M, Nadatani Y, Fukunaga S, Otani K, Tanaka F, Fujiwara Y

doi: 10.1093/ibd/izaf302

Helicobacter Pylori

An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of a 7-Day Triple Therapy With Bismuth Versus 14-Day Standard Triple Therapy for Helicobacter pylori Eradication in Children and Adolescents

Helicobacter

Šterbenc A, Vratanar B, Mojškerc EM, Homan M

doi: 10.1111/hel.70103

Gastrointestinal Cancer

Real-world outcomes of adjuvant therapy after curative-intent resection for biliary tract cancer

Eur J Cancer

Dong Y, Pereyra D, Podrascanin V, Li Z, Santol J, Ammann M, Hardy N, Kankeu Fonkoua LA, Graham RP, Conboy CB, Tran NH, Warner SG, Smoot RL, Starlinger PP

doi: 10.1016/j.ejca.2026.116887

Related content

Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResource

Comparative Risk of Serious Infections Associated With Treatment of Inflammatory Bowel Disease

Individuals with polyps ≥10mm without other high-risk features have a similarly low post-colonoscopy colorectal cancer risk as those with no polyps

Safety and outcomes of advanced IBD therapies in patients with HIV: a propensity-matched cohort analysis

Utility of quantitative fecal immunochemical test values for average risk colorectal cancer screening risk stratification among patients with a positive test

Dietary Iron Intake and Risk of Gastric Cancer

Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis

An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of a 7-Day Triple Therapy With Bismuth Versus 14-Day Standard Triple Therapy for Helicobacter pylori Eradication in Children and Adolescents

Real-world outcomes of adjuvant therapy after curative-intent resection for biliary tract cancer